secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001104659-26-053102
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio reports preliminary Q1 revenue of $19.0M; Chairman and three directors to resign, new directors appointed
--------------------------------------------------------------------------------

- Preliminary Q1 2026 revenue approximately $19.0M; unaudited and subject to change after close.
- Chairman Doug Evans and directors Kurt Azarbarzin, Vince Burgess, Federica O'Brien to resign after 2026 annual meeting.
- Board nominates Joseph Capper (CEO of MiMedx) for election as Class I director and future Chairman.
- Board appoints Guido Neels, Guy Nohra, Paul Thomas as new directors effective after 2026 annual meeting.
- Incoming directors and Capper to receive initial equity awards: options for 17,550 shares and RSUs for 11,925 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/tm2612982d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-053102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer